To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Puberty Suppressing Hormones: Clinical Trials
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they intend to extend the terms of the PATHWAYS puberty blockers trial to assess the well-being of the participants into adulthood, after the end of the trial.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency and the Health Research Authority have approved a research protocol for the PATHWAYS clinical trial, setting out the clinical and research eligibility criteria for participation, including exclusion and discontinuation criteria relating to bone density, and the full range of necessary information for participants and their parents on issues such as fertility preservation.

The protocol also sets out the extensive care and monitoring that will apply both within and after the clinical trial. Once the initial period of the study is complete, all trial participants initiated on puberty suppressing hormones as part of the trial will be monitored via an open label, non-randomised extension of the current study. The National Institute for Health and Care Research has committed to funding this extension, subject to normal scientific review.

The Government is clear that people should only take prescription-only medicines that have been prescribed and dispensed by an appropriately qualified and licensed healthcare professional. Since 1 January 2025, restrictions on the sale and supply of puberty blockers via private prescriptions have been made indefinite. This legislation ensures that children will not be exposed to the unsafe prescribing of puberty blockers, and was introduced in response to recommendations in the Cass Review and following expert advice from the independent Commission on Human Medicines.

Children and their families are also strongly discouraged from sourcing any medication from unregulated or online providers that are not regulated by United Kingdom bodies. Where offences against this legislation are committed in the UK, the appropriate regulator can investigate and, where necessary, take action.


Written Question
Puberty Suppressing Hormones: Clinical Trials
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to ensure that children with existing bone health issues will not be recruited to the PATHWAYS puberty blockers trial.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency and the Health Research Authority have approved a research protocol for the PATHWAYS clinical trial, setting out the clinical and research eligibility criteria for participation, including exclusion and discontinuation criteria relating to bone density, and the full range of necessary information for participants and their parents on issues such as fertility preservation.

The protocol also sets out the extensive care and monitoring that will apply both within and after the clinical trial. Once the initial period of the study is complete, all trial participants initiated on puberty suppressing hormones as part of the trial will be monitored via an open label, non-randomised extension of the current study. The National Institute for Health and Care Research has committed to funding this extension, subject to normal scientific review.

The Government is clear that people should only take prescription-only medicines that have been prescribed and dispensed by an appropriately qualified and licensed healthcare professional. Since 1 January 2025, restrictions on the sale and supply of puberty blockers via private prescriptions have been made indefinite. This legislation ensures that children will not be exposed to the unsafe prescribing of puberty blockers, and was introduced in response to recommendations in the Cass Review and following expert advice from the independent Commission on Human Medicines.

Children and their families are also strongly discouraged from sourcing any medication from unregulated or online providers that are not regulated by United Kingdom bodies. Where offences against this legislation are committed in the UK, the appropriate regulator can investigate and, where necessary, take action.


Written Question
Puberty Suppressing Hormones: Clinical Trials
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they intend to preclude children in care from participating in the PATHWAYS puberty blockers trial.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency and the Health Research Authority have approved a research protocol for the PATHWAYS clinical trial, setting out the clinical and research eligibility criteria for participation, including exclusion and discontinuation criteria relating to bone density, and the full range of necessary information for participants and their parents on issues such as fertility preservation.

The protocol also sets out the extensive care and monitoring that will apply both within and after the clinical trial. Once the initial period of the study is complete, all trial participants initiated on puberty suppressing hormones as part of the trial will be monitored via an open label, non-randomised extension of the current study. The National Institute for Health and Care Research has committed to funding this extension, subject to normal scientific review.

The Government is clear that people should only take prescription-only medicines that have been prescribed and dispensed by an appropriately qualified and licensed healthcare professional. Since 1 January 2025, restrictions on the sale and supply of puberty blockers via private prescriptions have been made indefinite. This legislation ensures that children will not be exposed to the unsafe prescribing of puberty blockers, and was introduced in response to recommendations in the Cass Review and following expert advice from the independent Commission on Human Medicines.

Children and their families are also strongly discouraged from sourcing any medication from unregulated or online providers that are not regulated by United Kingdom bodies. Where offences against this legislation are committed in the UK, the appropriate regulator can investigate and, where necessary, take action.


Written Question
Puberty Suppressing Hormones: Clinical Trials
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking take to safeguard participants in the PATHWAYS puberty blockers trial and ensure that they do not access cross-sex-hormones illegally from the private sector.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency and the Health Research Authority have approved a research protocol for the PATHWAYS clinical trial, setting out the clinical and research eligibility criteria for participation, including exclusion and discontinuation criteria relating to bone density, and the full range of necessary information for participants and their parents on issues such as fertility preservation.

The protocol also sets out the extensive care and monitoring that will apply both within and after the clinical trial. Once the initial period of the study is complete, all trial participants initiated on puberty suppressing hormones as part of the trial will be monitored via an open label, non-randomised extension of the current study. The National Institute for Health and Care Research has committed to funding this extension, subject to normal scientific review.

The Government is clear that people should only take prescription-only medicines that have been prescribed and dispensed by an appropriately qualified and licensed healthcare professional. Since 1 January 2025, restrictions on the sale and supply of puberty blockers via private prescriptions have been made indefinite. This legislation ensures that children will not be exposed to the unsafe prescribing of puberty blockers, and was introduced in response to recommendations in the Cass Review and following expert advice from the independent Commission on Human Medicines.

Children and their families are also strongly discouraged from sourcing any medication from unregulated or online providers that are not regulated by United Kingdom bodies. Where offences against this legislation are committed in the UK, the appropriate regulator can investigate and, where necessary, take action.


Written Question
Puberty Suppressing Hormones: Clinical Trials
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that participants in the PATHWAYS puberty blockers trial do not remain on puberty blockers past the trial period.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency and the Health Research Authority have approved a research protocol for the PATHWAYS clinical trial, setting out the clinical and research eligibility criteria for participation, including exclusion and discontinuation criteria relating to bone density, and the full range of necessary information for participants and their parents on issues such as fertility preservation.

The protocol also sets out the extensive care and monitoring that will apply both within and after the clinical trial. Once the initial period of the study is complete, all trial participants initiated on puberty suppressing hormones as part of the trial will be monitored via an open label, non-randomised extension of the current study. The National Institute for Health and Care Research has committed to funding this extension, subject to normal scientific review.

The Government is clear that people should only take prescription-only medicines that have been prescribed and dispensed by an appropriately qualified and licensed healthcare professional. Since 1 January 2025, restrictions on the sale and supply of puberty blockers via private prescriptions have been made indefinite. This legislation ensures that children will not be exposed to the unsafe prescribing of puberty blockers, and was introduced in response to recommendations in the Cass Review and following expert advice from the independent Commission on Human Medicines.

Children and their families are also strongly discouraged from sourcing any medication from unregulated or online providers that are not regulated by United Kingdom bodies. Where offences against this legislation are committed in the UK, the appropriate regulator can investigate and, where necessary, take action.


Written Question
Gender Dysphoria: Health Services
Tuesday 3rd November 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what processes they have put in place to ensure that young people who transfer from NHS children and young people’s gender services to adult gender dysphoria clinics continue to receive safeguarding protections and holistic assessment equivalent to those recommended by the Cass Review before any hormonal or surgical treatment is offered.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

As recommended in his report of the operational and delivery review of NHS adult gender dysphoria clinics in England, Dr David Levy is working with a broad range of clinical specialties to develop a new, standardised biopsychosocial assessment, intended to be used across all adult gender services with the aim of ensuring the holistic needs of all patients are met. NHS England will hold a public consultation on the proposed new service specification for adult gender services before final decisions are made.


Written Question
Gender Dysphoria: Health Services
Wednesday 28th October 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 17 July (HL2263), whether they now intend to issue guidance to safeguarding leads in local authorities on how to respond when a parent disagrees with a child or young adult's wish to undergo social or medical transition; and if not, why not.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

On 1 April, NHS England published an updated service specification for NHS Children and Young People’s Gender Services, reflecting the findings and recommendations of the Cass Review. The specification makes clear that clinicians should consider safeguarding needs as part of the holistic assessment framework.

Additionally, on 1 September, the Department for Education published updated statutory Keeping Children Safe in Education guidance, which details how schools and colleges should support children and young people who are questioning their gender.


Written Question
Health Services: Gender Dysphoria
Wednesday 28th October 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 17 July (HL2263), what guidance, if any, they plan to issue to safeguarding leads in local authorities about situations where a parent disagrees with a child or young person's desire to undergo social or medical transition.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

On 1 April, NHS England published an updated service specification for NHS Children and Young People’s Gender Services, reflecting the findings and recommendations of the Cass Review. The specification makes clear that clinicians should consider safeguarding needs as part of the holistic assessment framework.

Additionally, on 1 September, the Department for Education published updated statutory Keeping Children Safe in Education guidance, which details how schools and colleges should support children and young people who are questioning their gender.


Written Question
Gender Dysphoria: Health Services
Wednesday 28th October 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what progress the NHS England has made on implementing recommendation 31 of the Cass review to ensure that professional bodies come together to provide leadership and guidance on the clinical management of the population seeking support through gender clinics.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

This recommendation has been actioned by NHS England by ensuring that there is senior representation on all the committees and working groups that have a role in delivery of the Cass Review recommendations. For example, NHS England has commissioned the Academy of Medical Royal Colleges to design the new education and training framework for clinicians working in NHS Children and Young People's Gender Services, with an expert steering group that includes representatives from twelve royal colleges and other professional bodies.


Written Question
Women's Prisons: Transgender People
Wednesday 28th October 2026

Asked by: Baroness Maclean of Redditch (Conservative - Life peer)

Question to the Ministry of Justice:

To ask His Majesty's Government, further to the Written Answer by Lord Lemos on 27 July (HL2715), how many exemptions were granted under the previous Government to permit a transgender woman who retained male genitalia, or who had been charged with or convicted of a sexual or violent offence, to be accommodated in the general women's estate; and how many such exemptions were granted in each of the past five years for which records are available.

Answered by Lord Lemos - Parliamentary Under-Secretary (Ministry of Justice)

The number of ministerial exemptions provided to transgender women since the exemption process was introduced in February 2023 is shown in the table below. For data protection reasons, the exact figure is not given where the total is five or fewer.

Year

Number of exemptions provided

2023

9

2024 – 1 Jan – 4 Jul

Five or fewer

2024 – 5 Jul – 31 Dec

0

2025

0

2026 to date

0